- ADC Therapeutics to Participate in Cowen 41st Annual Health Care Conference
- ADC Therapeutics to Participate in Guggenheim Healthcare Talks 2021 Oncology Day
- ADC Therapeutics Completes Enrollment in Pivotal Phase 2 Clinical Trial of Camidanlumab Tesirine (Cami) in Relapsed or Refractory Hodgkin Lymphoma
- ADC Therapeutics Initiates Expanded Access Program for Loncastuximab Tesirine in the U.S.
- ADC Therapeutics to Participate in SternIR Virtual Corporate Access Event
- ADC Therapeutics and Overland Pharmaceuticals Announce Formation of Overland ADCT BioPharma to Develop and Commercialize Lonca and other ADCs for Hematologic and Solid Tumor Indications in Greater China and Singapore
- ADC Therapeutics Announces Updated Clinical Data on Lead Antibody Drug Conjugate Programs Loncastuximab Tesirine (Lonca) and Camidanlumab Tesirine (Cami) Presented at 62nd American Society of Hematology Annual Meeting
- ADC Therapeutics to Host Conference Call Highlighting Data from its Next-Generation Antibody Drug Conjugates Being Presented at the 62nd American Society of Hematology Annual Meeting
ADC Therapeutics SA (ADCT:NYQ) closed at 26.59, 5.92% above its 52-week low of 25.11, set on Oct 21, 2020.
25.11Oct 21 202056.59Jul 02 2020
Markit short selling activity
|Market cap||2.04bn USD|
Data delayed at least 15 minutes, as of Feb 27 2021 00:00 GMT.